Jonathan D. Root - 16 Jun 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Director
Issuer ticker: EWTX
Reported as of: 16 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2025, 19:36:27 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 08 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ John R. Moore Attorney-in-Fact for Jonathan Root M.D.

Key filing fact

Jonathan D. Root filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 18 Jun 2025.

Key facts

This page summarizes Jonathan D. Root's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2025, 19:36.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001225480 Primary reporting owner

ROOT JONATHAN D

Relationship: Director
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: /s/ John R. Moore Attorney-in-Fact for Jonathan Root M.D.
Signature date: 18 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $14.68
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.